Literature DB >> 25814420

Outcomes of nonpharmacologic treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy.

Mohamed Bassiouny1, Bruce D Lindsay1, Harry Lever1, Walid Saliba1, Allan Klein1, Moustafa Banna1, JoEllyn Abraham2, Mingyuan Shao1, John Rickard3, Mohamed Kanj1, Patrick Tchou1, Thomas Dresing1, Bryan Baranowski1, Mandeep Bhargava1, Thomas Callahan1, Khaldoun Tarakji1, Daniel Cantillon1, Ayman Hussein1, A Marc Gillinov4, Nicholas G Smedira4, Oussama Wazni5.   

Abstract

BACKGROUND: Limited data exist regarding the outcome of atrial fibrillation (AF) surgery and catheter ablation in patients with hypertrophic cardiomyopathy (HCM).
OBJECTIVE: The purpose of this study was to evaluate the safety and efficacy of nonpharmacologic treatment of AF in HCM.
METHODS: One hundred forty-seven patients (46 female, age 55 ± 11 years, ejection fraction [EF] 58% ± 8%) with symptomatic paroxysmal (58%), persistent (31%), and long-standing persistent AF (11%) refractory to antiarrhythmic drugs who presented for their first catheter ablation (n = 79) or AF surgery (n = 68) were included.
RESULTS: After follow-up of 35 months (interquartile range 13, 60), 29% of patients who underwent catheter ablation and 51% of those who had undergone AF surgery had no documented recurrent atrial arrhythmia after a single procedure. Repeat ablation was performed in 55% of patients with recurrent arrhythmia in the catheter group and 24% in the surgery group, increasing the success rate to 39% and 53%, respectively, after 1 or more procedures. Predictors of success after the first procedure in a multivariable setting included higher baseline EF and male gender. Persistent or long-standing AF and log of AF duration were associated with lower success. Major complications occurred in 6% of the catheter ablation group and 18% of the AF surgery group. During follow-up, 16 patients died (9 in catheter group, 7 in surgery group) and 1 underwent heart replacement. Lower baseline EF and older age were independently associated with death.
CONCLUSION: Catheter ablation and AF surgery are associated with symptomatic improvement in HCM patients. However, long-term success is lower and complications are higher than previously reported.
Copyright © 2015 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Catheter ablation; Hypertrophic cardiomyopathy; Maze procedure; Pulmonary vein isolation; Surgery

Mesh:

Year:  2015        PMID: 25814420     DOI: 10.1016/j.hrthm.2015.03.042

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  10 in total

1.  Research Needs and Priorities for Catheter Ablation of Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop.

Authors:  Sana M Al-Khatib; Emelia J Benjamin; Alfred E Buxton; Hugh Calkins; Mina K Chung; Anne B Curtis; Patrice Desvigne-Nickens; Pierre Jais; Douglas L Packer; Jonathan P Piccini; Yves Rosenberg; Andrea M Russo; Paul J Wang; Lawton S Cooper; Alan S Go
Journal:  Circulation       Date:  2019-11-20       Impact factor: 29.690

Review 2.  Atrial Fibrillation in Hypertrophic Cardiomyopathy: Diagnosis and Considerations for Management.

Authors:  Monica Patten; Simon Pecha; Ali Aydin
Journal:  J Atr Fibrillation       Date:  2018-02-28

Review 3.  Targeted Medical Therapies for Hypertrophic Cardiomyopathy.

Authors:  Carlo Fumagalli; Maria Grazia De Gregorio; Mattia Zampieri; Elisa Fedele; Alessia Tomberli; Chiara Chiriatti; Alberto Marchi; Iacopo Olivotto
Journal:  Curr Cardiol Rep       Date:  2020-01-28       Impact factor: 2.931

4.  Outcomes in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a survival meta-analysis.

Authors:  Ahmad Masri; Mohamed Kanj; Maran Thamilarasan; Oussama Wazni; Nicholas G Smedira; Harry M Lever; Milind Y Desai
Journal:  Cardiovasc Diagn Ther       Date:  2017-02

Review 5.  Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management.

Authors:  Lohit Garg; Manasvi Gupta; Syed Rafay Ali Sabzwari; Sahil Agrawal; Manyoo Agarwal; Talha Nazir; Jeffrey Gordon; Babak Bozorgnia; Matthew W Martinez
Journal:  Heart Fail Rev       Date:  2019-03       Impact factor: 4.214

Review 6.  Who Needs Catheter Ablation And Which Approach?

Authors:  Duygu Kocyigit; Ugur Canpolat; Kudret Aytemir
Journal:  J Atr Fibrillation       Date:  2015-12-31

7.  Concomitant Cox-Maze IV and Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy.

Authors:  Nadia H Bakir; Robert M MacGregor; Ali J Khiabani; Farah N Musharbash; Matthew R Schill; Laurie A Sinn; Richard B Schuessler; Spencer J Melby; Marye J Gleva; Ralph J Damiano
Journal:  Ann Thorac Surg       Date:  2021-03-01       Impact factor: 5.102

8.  Utilization and Complications of Catheter Ablation for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy.

Authors:  Guy Rozen; Gabby Elbaz-Greener; Ibrahim Marai; Nizar Andria; Seyed Mohammadreza Hosseini; Yitschak Biton; E Kevin Heist; Jeremy N Ruskin; Yulia Gavrilov; Shemy Carasso; Diab Ghanim; Offer Amir
Journal:  J Am Heart Assoc       Date:  2020-06-23       Impact factor: 5.501

9.  Ablation of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy: Treatment Strategy, Characteristics of Consecutive Atrial Tachycardia and Long-Term Outcome.

Authors:  Leon Dinshaw; Paula Münkler; Benjamin Schäffer; Niklas Klatt; Christiane Jungen; Jannis Dickow; Annika Tamenang; Ruben Schleberger; Simon Pecha; Hans Pinnschmidt; Monica Patten; Hermann Reichenspurner; Stephan Willems; Christian Meyer
Journal:  J Am Heart Assoc       Date:  2021-01-17       Impact factor: 5.501

10.  Pulmonary vein isolation implemented by second-generation cryoballoon for treating hypertrophic cardiomyopathy patients with symptomatic atrial fibrillation: a case-control study.

Authors:  Zhong-Jing Cao; Xiao-Gang Guo; Qi Sun; Jian-Du Yang; Hui-Qiang Wei; Shu Zhang; Jian Ma
Journal:  J Geriatr Cardiol       Date:  2020-08       Impact factor: 3.327

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.